Real-world efficacy and safety of transarterial chemoembolization plus sintilimab and bevacizumab biosimilar for intermediate-advanced hepatocellular carcinoma: a propensity score matching study.
Saved in:
| Title: | Real-world efficacy and safety of transarterial chemoembolization plus sintilimab and bevacizumab biosimilar for intermediate-advanced hepatocellular carcinoma: a propensity score matching study. |
|---|---|
| Authors: | Deng LW; Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China., Liu JF; Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China., Yu HY; Department of Oncology, Xuanhan County People's Hospital, Dazhou, Sichuan, China., Peng B; Department of Interventional Radiology, Chengdu Second People's Hospital, Chengdu, China., Liu B; Department of Tumor Vascular Intervention, Chengdu Qingbaijiang District People's Hospital, Chengdu, China., Feng SF; Department of General Surgery, Chengdu Public Health Clinical Medical Center, Chengdu, China., Liu DX; Department of General Surgery, Chengdu Public Health Clinical Medical Center, Chengdu, China., Sun YY; Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China., Chen Y; Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China., Chen JJ; Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China., Zhang C; Department of Radiology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China., Wang HQ; Department of Hepatopancreatobiliary Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China., Xu GH; Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China., Liu L; Department of Interventional Radiology, Chengdu Second People's Hospital, Chengdu, China., Wei G; Department of General Surgery, Chengdu Public Health Clinical Medical Center, Chengdu, China., Ren Y; Department of Interventional Radiology, Chengdu Second People's Hospital, Chengdu, China., Cao L; Department of Tumor Vascular Intervention, Chengdu Qingbaijiang District People's Hospital, Chengdu, China., Zhao Y; Department of General Surgery, Chengdu Public Health Clinical Medical Center, Chengdu, China., Yang XG; Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China. |
| Source: | Frontiers in immunology [Front Immunol] 2026 Apr 10; Vol. 17, pp. 1748142. Date of Electronic Publication: 2026 Apr 10 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2026.1748142 |
